EWA
AMLX icon

EverSource Wealth Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

EverSource Wealth Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.29K Buy
350
+324
+1,246% +$5.01K ﹤0.01% 3166
2026
Q1 		$361 Buy
26
+1
+4% +$14 ﹤0.01% 4113
2025
Q4 		$302 Hold
25
– – ﹤0.01% 3965
2025
Q3 		$340 Hold
25
– – ﹤0.01% 4030
2025
Q2 		$160 Hold
25
– – ﹤0.01% 4077
2025
Q1 		$89 Hold
25
– – ﹤0.01% 3844
2024
Q4 		$95 Buy
+25
New +$118 ﹤0.01% 3549

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

EverSource Wealth Advisors's AMLX Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Amylyx Pharmaceuticals (AMLX) stake by 1,246% in Q2 2026, buying an estimated $5.01K and bringing the position to 350 shares worth $6.29K. The position accounts for ﹤0.01% of the portfolio, ranked #3166.

EverSource Wealth Advisors first reported a position in AMLX in Q4 2024 and has held it in 7 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • EverSource Wealth Advisors held 350 shares of Amylyx Pharmaceuticals worth $6.29K as of Q2 2026.
  • EverSource Wealth Advisors bought 324 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $5.01K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3166 holding.
  • EverSource Wealth Advisors first reported a position in Amylyx Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.